Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens

Vaccine

Volumn 33, Issue 9, 2015, Pages 1143-1150

  Yang, Yanli ^a,b   Li, Hao ^a,b   Li, Zhengjun ^a,b   Zhang, Yan ^a   Zhang, Songping ^a   Chen, Yi ^a,b   Yu, Mengran ^a,b   Ma, Guanghui ^a   Su, Zhiguo ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Quality control; Size exclusion HPLC; Vaccine; Virus; Virus like particles

Indexed keywords

FOOT AND MOUTH DISEASE VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN STRUCTURE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DISSOCIATION; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG QUALITY; DRUG STORAGE; ESCHERICHIA COLI; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOST CELL; LIGHT SCATTERING; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; QUALITY CONTROL; SIZE EXCLUSION HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THERMOSTABILITY; TRANSMISSION ELECTRON MICROSCOPY; VIRUS LIKE AGENT; VIRUS PARTICLE; HUMAN; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES; SIZE EXCLUSION CHROMATOGRAPHY; STANDARDS; TIME;

ANTIGENS, VIRAL; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; QUALITY CONTROL; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; VIRAL VACCINES;

EID: 84922929813     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.031     Document Type: Article

References (27)

1. Metz B., van den Dobbelsteen G., van Els C., van der Gun J., Levels L., van der Pol L., et al. Quality-control issues and approaches in vaccine development. Expert Rev Vaccines 2009, 8:227-238.
2. Garcia-Cañas V., Lorbetskie B., Girard M. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. J Chromatogr A 2006, 1123:225-232.
3. Cabral G.A., Marcianocabral F., Funk G.A., Sanchez Y., Hollinger F.B., Melnick J.L., et al. Cellular and humoral immunity in guinea pigs to 2 major polypeptides derived from hepatitis B surface antigen. J Gen Virol 1978, 38:339-350.
4. Zhou W., Bi J., Janson J-C., Dong A., Li Y., Zhang Y., et al. Ion-exchange chromatography of hepatitis B virus surface antigen from a recombinant Chinese hamster ovary cell line. J Chromatogr A 2005, 1095:119-125.
5. Harmsen M.M., Fijten H.P., Westra D.F., Coco-Martin J.M. Effect of thiomersal on dissociation of intact (146S) foot-and-mouth disease virions into 12S particles as assessed by novel ELISAs specific for either 146S or 12S particles. Vaccine 2011, 29:2682-2690.
6. Doel T.R., Baccarini P.J. Thermal stability of foot-and-mouth disease virus. Arch Virol 1981, 70:21-32.
7. Brown F., Cartwright B. Dissociation of foot-and-mouth disease virus into its nucleic acid and protein components. Nature 1961, 192:1163-1164.
8. Rao M.G., Butchaiah G., Sen A.K. Antibody response to 146S particle, 12S protein subunit and isolated VP1 polypeptide of foot-and-mouth disease virus type Asia-1. Vet Microbiol 1994, 39:135-143.
9. Muhammad K., Chaudhry Z.I., Rabbani M., Altaf I., Tariq M.A., Anees M. In process quality control factors affecting potency of foot and mouth disease virus vaccine. Pak J Zool 2011, 43:249-254.
10. Saravanan P., Sen A., Balamurugan V., Bandyopadhyay S.K., Singh R.K. Rapid quality control of a live attenuated Peste des petits ruminants (PPR) vaccine by monoclonal antibody based sandwich ELISA. Biologicals 2008, 36:1-6.
11. Metz B., Hendriksen C.F.M., Jiskoot W., Kersten G.F.A. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine 2002, 20:2411-2430.
12. Le C.T., Grambsch P.M., Giebink G.S. Quality control and the identification of vaccine responders using ELISA-derived antibody data. Stat Med 2003, 22:2935-2942.
13. Rodriguez L.L., Grubman M.J. Foot and mouth disease virus vaccines. Vaccine 2009, 27:D90-D4.
14. Garcia-Canas V., Lorbetskie B., Cyr T.D., Hefford M.A., Smith S., Girard M. Approach to the profiling and characterization of influenza vaccine constituents by the combined use of size-exclusion chromatography, gel electrophoresis and mass spectrometry. Biologicals 2010, 38:294-302.
15. Pease L.F., Lipin D.I., Tsai D-H., Zachariah M.R., Lua L.H.L., Tarlov M.J., et al. Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol Bioeng 2009, 102:845-855.
16. Cole K.D., Pease L.F., Tsai D.-H., Singh T., Lute S., Brorson K.A., et al. Particle concentration measurement of virus samples using electrospray differential mobility analysis and quantitative amino acid analysis. J Chromatogr A 2009, 1216:5715-5722.
17. Chuan Y.P., Fan Y.Y., Lua L., Middelberg A.P.J. Quantitative analysis of virus-like particle size and distribution by field-flow fractionation. Biotechnol Bioeng 2008, 99:1425-1433.
18. Bousse T., Shore D.A., Goldsmith C.S., Hossain M.J., Jang Y., Davis C.T., et al. Quantitation of influenza virus using field flow fractionation and multi-angle light scattering for quantifying influenza A particles. J Virol Methods 2013, 193:589-596.
19. Wei Z., Mcevoy M., Razinkov V., Polozova A., Li E., Casas-Finet J., et al. Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity. J Virol Methods 2007, 144:122-132.
20. Spitteler M.A., Fernandez I., Schabes E., Krimer A., Regulier E.G., Guinzburg M., et al. Foot and mouth disease (FMD) virus: quantification of whole virus particles during the vaccine manufacturing process by size exclusion chromatography. Vaccine 2011, 29:7182-7187.
21. Barteling S.J., Meloen R.H. A simple method for the quantification of 140S particles of foot-and-mouth disease virus (FMDV). Arch Gesamte Virusforsch 1974, 45:362-364.
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
23. Bachrach H.L., Trautman R., Breese S.S. Chemical physical properties of virtually pure foot-and-mouth disease virus. Am J Vet Res 1964, 25:333-342.
24. Sobrino F., Sáiz M., Jiménez-Clavero M.A., Núñez J.I., Rosas M.F., Baranowski E., et al. Foot-and-mouth disease virus: a long known virus, but a current threat. Vet Res 2001, 32:1-30.
25. Yoon K.Y., Tan W.S., Tey B.T., Lee K.W., Ho K.L. Native agarose gel electrophoresis and electroelution: a fast and cost-effective method to separate the small and large hepatitis B capsids. Electrophoresis 2013, 34:244-253.
26. Pasek M., Goto T., Gilbert W., Zink B., Schaller H., Mackay P., et al. Hepatitis B virus genes and their expression in Escherichia-coli. Nature 1979, 282:575-579.
27. Lua L.H.L., Connors N.K., Sainsbury F., Chuan Y.P., Wibowo N., Middelberg A.P.J. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 2014, 111:425-440.